Truist Financial Cuts Medpace (NASDAQ:MEDP) Price Target to $539.00

Medpace (NASDAQ:MEDP) had its target price decreased by Truist Financial from $555.00 to $539.00 in a report issued on Wednesday morning, Marketbeat reports. Truist Financial currently has a hold rating on the stock.

MEDP has been the subject of several other reports. Robert W. Baird raised shares of Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 target price for the company in a report on Tuesday. Weiss Ratings restated a “buy (b)” rating on shares of Medpace in a research report on Wednesday, January 28th. Zacks Research cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th. Wall Street Zen upgraded Medpace from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. Finally, Barclays raised their price target on Medpace from $485.00 to $525.00 and gave the company an “underweight” rating in a report on Monday, December 15th. Four research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $487.36.

Medpace Stock Performance

Medpace stock opened at $428.03 on Wednesday. Medpace has a one year low of $250.05 and a one year high of $628.92. The stock has a fifty day moving average of $567.52 and a 200 day moving average of $537.72. The stock has a market cap of $12.15 billion, a PE ratio of 27.98, a price-to-earnings-growth ratio of 1.99 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.18 by $0.49. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The business had revenue of $708.45 million during the quarter, compared to the consensus estimate of $689.53 million. During the same period in the previous year, the company posted $3.67 EPS. The business’s quarterly revenue was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, sell-side analysts predict that Medpace will post 12.29 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO August J. Troendle sold 59,025 shares of the business’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $607.78, for a total value of $35,874,214.50. Following the sale, the chief executive officer directly owned 774,602 shares in the company, valued at $470,787,603.56. The trade was a 7.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Susan E. Burwig sold 20,000 shares of the company’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the sale, the vice president owned 27,500 shares in the company, valued at $16,751,625. This represents a 42.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 270,533 shares of company stock valued at $163,122,826 over the last three months. Corporate insiders own 20.30% of the company’s stock.

Hedge Funds Weigh In On Medpace

Several large investors have recently modified their holdings of the stock. Quent Capital LLC bought a new stake in Medpace in the third quarter worth $25,000. Optiver Holding B.V. purchased a new stake in shares of Medpace in the third quarter valued at $27,000. Geneos Wealth Management Inc. raised its stake in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares during the period. Steigerwald Gordon & Koch Inc. bought a new stake in shares of Medpace in the 4th quarter worth about $30,000. Finally, Elyxium Wealth LLC purchased a new position in shares of Medpace during the 4th quarter worth about $30,000. Institutional investors own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.